

Clinical Policy: Lumasiran (Oxlumo)

Reference Number: CP.PHAR.473

Effective Date: 11.23.20

Last Review Date: 02.22

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Lumasiran (Oxlumo[™]) is an RNAi therapeutic targeting glycolate oxidase (GO).

FDA Approved Indication(s)

Oxlumo is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Oxlumo is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Primary Hyperoxaluria Type 1 (must meet all):**

1. Diagnosis of PH type 1 confirmed by one of the following (a or b):
 - a. Genetic testing confirming presence of mutations in the *AGXT* gene;
 - b. Liver biopsy confirming AGT enzyme deficiency;
2. Prescribed by or in consultation with an endocrinologist, hepatologist, or nephrologist;
3. Documentation of one of the following (a or b):
 - a. Urinary oxalate (UOx) excretion $> 0.70 \text{ mmol}/1.73 \text{ m}^2/24 \text{ h}$, confirmed on repeat testing;
 - b. Spot urinary oxalate-to-creatinine (UOx:Cr) molar ratio greater than normal for age (*see Appendix D for reference ranges*), confirmed on repeat testing;
4. Documentation of estimated glomerular filtration rate (eGFR) $> 30 \text{ mL}/\text{min}/1.73 \text{ m}^2$;
5. Failure to achieve normalization of UOx excretion levels after at least three months of pyridoxine (vitamin B6) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
**Normal UOx excretion is $< 0.50 \text{ mmol}$ ($< 45 \text{ mg}$)/ $1.73 \text{ m}^2/\text{day}$, or see Appendix D for reference ranges for age-specific spot UOx:Cr molar ratios.*
6. Member has not had a liver transplant;
7. Documentation of member's current body weight (in kg);
8. Dose does not exceed any of the following, based on body weight (a, b, or c):
 - a. $< 10 \text{ kg}$: 6 mg/kg per month for 3 doses followed by 3 mg/kg per month;
 - b. 10 kg to $< 20 \text{ kg}$: 6 mg/kg per month for 3 doses followed by 6 mg/kg every 3 months;

- c. ≥ 20 kg: 3 mg/kg per month for 3 doses followed by 3 mg/kg every 3 months.
- Approval duration: 6 months**

B. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Primary Hyperoxaluria Type 1 (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy as evidenced by one of the following (a or b):
 - a. Decrease from baseline in UOx excretion of $> 30\%$;
 - b. Decrease from baseline in UOx excretion or improvement in spot UOx:Cr molar ratio, along with improvement in PH1 symptoms (e.g., nephrolithiasis, nephrocalcinosis, kidney function, ischemic skin ulcers, metabolic bone disease, refractory anemia, cardiomyopathy, abnormalities in cardiac conduction);
3. Member has not had a liver transplant;
4. Documentation of member's current body weight (in kg);
5. If request is for a dose increase, new dose does not exceed any of the following, based on body weight (a, b, or c):
 - a. < 10 kg: 3 mg/kg per month;
 - b. 10 kg to < 20 kg: 6 mg/kg every 3 months;
 - c. ≥ 20 kg: 3 mg/kg every 3 months.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 6 months (whichever is less); or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

eGFR: estimated glomerular filtration rate

FDA: Food and Drug Administration

GO: glycolate oxidase

PH1: primary hyperoxaluria type 1

RNAi: RNA interference

UOx: urinary oxalate

UOx:Cr: urinary oxalate-to-creatinine

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
pyridoxine	5-20 mg/kg PO QD	20 mg/kg/day

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

None reported

Appendix D: Spot UOx/Cr Molar Ratio Reference Ranges in Spot Urine Samples

Age	Normal Values
0-6 months	< 325-360 mmol/mol (< 253-282 mg/g)
7-24 months	< 132-174 mmol/mol (< 103-136 mg/g)
2-5 years	< 98-101 mmol/mol (< 76-79 mg/g)
5-14 years	< 70-82 mmol/mol (< 55-64 mg/g)
> 16 years	< 40 mmol/mol (< 32 mg/g)

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
PH1	If weight is: < 10 kg: 6 mg/kg/month for 3 doses followed by 3 mg/kg/month; 10 kg to < 20 kg: 6 mg/kg/month for 3 doses followed by 6 mg/kg every 3 months; ≥ 20 kg: 3 mg/kg/month for 3 doses followed by 3 mg/kg every 3 months	If weight is: < 10 kg: 3 mg/kg/month; 10 kg to < 20 kg: 6 mg/kg every 3 months; ≥ 20 kg: 3 mg/kg every 3 months

VI. Product Availability

Solution in single-dose vial: 94.5 mg/0.5 mL

VII. References

1. OxLumo Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc. November 2020. Available at www.OxLumo.com. Accessed November 19, 2021.

2. Milliner DS, Harris PC, Cogal AG, et al. Primary hyperoxaluria type 1. 2002 Jun 19 [Updated 2017 Nov 30]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1283/pdf/Bookshelf_NBK1283.pdf. Accessed December 9, 2020.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
C9074	Injection, lumasiran, 0.5 mg
C9399	Unclassified drugs or biologicals

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created pre-emptively	03.03.20	05.20
Drug is now FDA approved – criteria updated per FDA labeling: added hepatologist and nephrologist specialists; added spot UOx/Cr molar ratio as an additional option for biochemical confirmation of PH1 diagnosis; added requirement for no prior liver transplant; added requirement for documentation of current weight in kg; added ability to reauthorize based on improvements in symptoms; updated reference for HIM off-label use to HIM.PA.154 (replaces HIM.PHAR.21); references reviewed and updated.	01.05.21	02.21
Revised requirement for a minimum response to pyridoxine treatment from “> 30% reduction in UOx excretion” to “normalization of UOx excretion levels”; for reauthorization added improvement in spot UOx:Cr molar ratio along with symptomatic improvement as a pathway for reauthorization; references reviewed and updated.	06.06.21	08.21
1Q 2022 annual review: no significant changes; references reviewed and updated.	11.19.21	02.22

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in

developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2020 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international

copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.